A Ashkenazi

A Garg

A Tecleab

B Mojsa

CS Bestwick

DC Altieri

E Szliszka

H Huang

H Ren

H Zhang

H-T Zhang

HT Zhang

L Chang

L Su

L Zhao

LW Thomas

M Wen

MY Heo

R Zobalova

RJ Tallarida

RK Srivastava

S Ramos

SD Catz

T Miyashita

TJ Murray

TK Ha

TS Griffith

V Arora

W Zhang

Y Zhang

Scientific Reports

AbstractGalangin, bioflavonoids, has been shown anti-cancer properties in various cancer cells. In this study, we investigated whether galangin could enhance TRAIL-mediated apoptosis in TRAIL resistant renal carcinoma Caki cells. Galangin alone and TRAIL alone had no effect on apoptosis, while combined treatment with galangin and TRAIL significantly induced apoptosis in renal carcinoma (Caki, ACHN and A498) but not normal cells (normal mouse kidney cells and human normal mesangial cells). Galangin induced down-regulation of Bcl-2 protein at the transcriptional level via inhibition of NF-κB activation but not p53 pathway. Furthermore, galangin induced down-regulation of cFLIP, Mcl-1 and survivin expression at the post-translational levels and the over-expression of Bcl-2, cFLIP, Mcl-1 and survivin markedly reduced galangin-induced TRAIL sensitization. In addition, galangin increased proteasome activity, but galangin had no effect on expression of proteasome subunits (PSMA5 and PSMD4). In conclusion, our investigation suggests that galangin is a potent candidate for sensitizer of TRAIL resistant cancer cell therapy.</jats:p

Min Ae Han

Dong Hee Lee

Seon Min Woo

Bo Ram Seo

Kyoung-jin Min

Shin Kim

Jong-Wook Park

Sang Hyun Kim

Yung Hyun Choi

Taeg Kyu Kwon

Crossref

Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells

Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells

Abstract

Similar works

Full text

Available Versions

Crossref